# MI:RNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mi-rna

- Industry: Healthcare
- Headquarters: Edinburgh, UK
- Website: www.mirna-diagnostics.com/en
- Total disclosed funding: $4M
- Latest round: Series A (Jul 1, 2024)
- Investors on record: 6

## About

Based in the UK, MI:RNA Ltd. specializes in veterinary diagnostics, focusing on innovative technologies for early detection of heart disease and other conditions in animals. 

MI:RNA Ltd. is dedicated to providing advanced diagnostic solutions for veterinary practices. Founded in 2019 by Eve Hanks who is also the CEO, in Edinburgh, UK, the company has successfully completed three deals to date. Recently, In December 2025, MI:RNA Ltd. raised USD 3.6 million in venture funding from Holstein UK and Ani.vc, NovaQuest Capital Management, Scottish Enterprise, Kyoritsu Holdings Corporation, Veterinary Angel Network, Animal Health Angels, Equity Gap and Gabriel Investments Ltd. 

MI:RNA Diagnostics specializes in veterinary diagnostics, focusing on innovative technologies to detect early-stage heart disease and other conditions in companion and production animals. Their flagship product utilizes serum biomarkers and AI modeling to provide accurate diagnostics, enabling veterinarians to enhance disease monitoring and treatment response for pets, specifically targeting cardiac health in cats and dogs. Additionally, the company is engaged in research related to Johne’s disease screening in production animals, aimed at reducing animal suffering, lowering farmer costs, and contributing to environmental sustainability. MI:RNA's services cater to veterinary practices and agricultural businesses across Europe and North America, providing a comprehensive diagnostic platform that stands to revolutionize animal healthcare by offering veterinarians valuable tools to improve patient outcomes.

MI:RNA Diagnostics operates on a business-to-business model, primarily serving veterinary practices and agricultural enterprises. Revenue generation is largely driven through the provision of diagnostic services and products, where veterinary practices may incorporate MI:RNA's testing capabilities into their service offerings. Transactions typically involve direct sales agreements, where veterinary clinics pay for diagnostic tests on a per-use basis or potentially through subscription models that provide ongoing access to the company's diagnostic technology. MI:RNA’s products include proprietary diagnostic tests tailored specifically for different animal health issues, enhancing their value proposition in the marketplace.

MI:RNA Ltd. plans to support expansion of its veterinary diagnostics platform, including scaling commercial activities, increasing partnerships with laboratory networks across different regions, and continuing development and validation of its biomarker-based diagnostic models for broader deployment.

## Funding rounds

- Series A, Jul 1, 2024, $4M — NovaQuest Capital Management, Equity Gap, Scottish Enterprise, Gabriel Investments Ltd., Kyoritsu Holdings, Animal Health Angels

## Investors

- NovaQuest Capital Management (https://capitalatlas.ai/funds/novaquest-capital-management) — Series A
- Equity Gap (https://capitalatlas.ai/funds/equity-gap) — Series A
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series A
- Gabriel Investments Ltd. — Series A
- Kyoritsu Holdings — Series A
- Animal Health Angels — Series A